Solid Tumor Cancer Treatment With Immunotherapy Clinical Trials in Fuzhou, Fujian

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors